secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004133
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon appoints commercial executive William 'BJ' Jones to board of directors
------------------------------------------------------------------------------

- William 'BJ' Jones appointed to Board as Class I director effective Jan 9, 2025, term through 2027 annual meeting.
- Receives $40K annual retainer, initial 88K-share option (3-yr monthly vest), and 44K-share annual option.
- Jones brings 30 years commercial launch experience; currently CCO at NewAmsterdam Pharma; previously at Biohaven (acquired by Pfizer for $11.6B).
- Company notes his expertise valuable as ANX005 (Guillain-Barré Syndrome) and ANX007 (geographic atrophy) approach commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312525004133/0001193125-25-004133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312525004133/d796195d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer